2019
Hyperprogression after one dose of nivolumab in sinonasal cancer: A case report
Xiang JJ, Uy NF, Minja FJ, Verter EE, Burtness BA. Hyperprogression after one dose of nivolumab in sinonasal cancer: A case report. The Laryngoscope 2019, 130: 907-910. PMID: 31058321, DOI: 10.1002/lary.28042.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsDose of nivolumabSquamous cell carcinomaSinonasal cancerCell carcinomaDisease progressionMaxillary sinus squamous cell carcinomaSinus squamous cell carcinomaNeck squamous cell carcinomaComplete vision lossICI initiationCheckpoint inhibitorsFirst doseLytic metastasesDistal metastasisCase reportIntracranial invasionVision lossImproved outcomesHyperprogressionIndividual riskDoseNivolumabCarcinomaMetastasisRadiation therapy treatment facility and overall survival in the adjuvant setting for locally advanced head and neck squamous cell carcinoma
Lee NCJ, Kelly JR, An Y, Park HS, Judson BL, Burtness BA, Husain ZA. Radiation therapy treatment facility and overall survival in the adjuvant setting for locally advanced head and neck squamous cell carcinoma. Cancer 2019, 125: 2018-2026. PMID: 30748002, PMCID: PMC6541535, DOI: 10.1002/cncr.32001.Peer-Reviewed Original ResearchConceptsHigh-volume surgical facilitiesPostoperative radiation therapyNeck squamous cell carcinomaSquamous cell carcinomaOverall survivalSurvival benefitCell carcinomaSurgical facilitiesPropensity score-matched cohortAnnual case volumeDefinitive surgeryAdvanced headOS improvementImproved outcomesRadiation therapyCase volumeOral cavityPatientsReduced hazardMultivariate analysisSurgeryInvasive HNSCCCarcinomaSurvivalTreatment
2018
Adjuvant therapy in major salivary gland cancers: Analysis of 8580 patients in the National Cancer Database
Cheraghlou S, Kuo P, Mehra S, Agogo GO, Bhatia A, Husain ZA, Yarbrough WG, Burtness BA, Judson BL. Adjuvant therapy in major salivary gland cancers: Analysis of 8580 patients in the National Cancer Database. Head & Neck 2018, 40: 1343-1355. PMID: 29756412, DOI: 10.1002/hed.24984.Peer-Reviewed Original ResearchConceptsNational Cancer Data BaseLate-stage diseaseAdjuvant treatmentSalivary gland cancerAdverse featuresAdjuvant radiotherapyImproved survivalGland cancerMajor salivary gland cancerAddition of chemotherapyNational Cancer DatabaseAdjuvant therapySurvival benefitRetrospective studyCancer DatabaseImproved outcomesCancer casesPatientsChemotherapyDiseaseTreatmentRadiotherapySurvivalCancerTherapy
2006
Antibody therapy for early-stage breast cancer: trastuzumab adjuvant and neoadjuvant trials
Mehra R, Burtness B. Antibody therapy for early-stage breast cancer: trastuzumab adjuvant and neoadjuvant trials. Expert Opinion On Biological Therapy 2006, 6: 951-962. PMID: 16918262, DOI: 10.1517/14712598.6.9.951.Peer-Reviewed Original ResearchConceptsBreast cancerVascular endothelial growth factor levelsEarly-stage breast cancerYear of trastuzumabHER2/neu geneGrowth factor levelsBreast cancer cellsAdjuvant settingNeoadjuvant trialsOverall survivalRandomised trialsAggressive courseImproved outcomesImmune responseTrastuzumabActivation initiatesFactor levelsHER2 phosphorylationMonoclonal antibodiesNeu geneCancerCancer cellsHER2TrialsAntibodies